OmniAb Inc
OABI2.050USD
-0.040-1.91%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
295.11MMarket Cap
LossP/E TTM
More Details of OmniAb Inc Company
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
OmniAb Inc Info
Ticker SymbolOABI
Company nameOmniAb Inc
IPO dateOct 09, 2020
CEOFoehr (Matthew William)
Number of employees114
Security typeOrdinary Share
Fiscal year-endOct 09
Address5980 Horton Street
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15102507800
Websitehttps://www.omniab.com/
Ticker SymbolOABI
IPO dateOct 09, 2020
CEOFoehr (Matthew William)
Company Executives of OmniAb Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.93M
+2.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
246.41K
+10.09%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
93.31K
+23.52%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
71.67K
+22.86%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.93M
+2.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
246.41K
+10.09%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
93.31K
+23.52%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
71.67K
+22.86%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Service revenue
1.94M
49.68%
License and milestone revenue
1.24M
31.87%
xPloration revenue
608.00K
15.60%
Royalty revenue
111.00K
2.85%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Service revenue
1.94M
49.68%
License and milestone revenue
1.24M
31.87%
xPloration revenue
608.00K
15.60%
Royalty revenue
111.00K
2.85%
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avista Capital Holdings, LP
10.99%
Whitefort Capital Management, LP
9.88%
Ash X LP
5.75%
BlackRock Institutional Trust Company, N.A.
4.38%
The Vanguard Group, Inc.
3.58%
Other
65.43%
Shareholders
Shareholders
Proportion
Avista Capital Holdings, LP
10.99%
Whitefort Capital Management, LP
9.88%
Ash X LP
5.75%
BlackRock Institutional Trust Company, N.A.
4.38%
The Vanguard Group, Inc.
3.58%
Other
65.43%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.08%
Investment Advisor
14.30%
Private Equity
10.99%
Investment Advisor/Hedge Fund
10.73%
Corporation
7.00%
Individual Investor
5.79%
Research Firm
0.94%
Pension Fund
0.10%
Bank and Trust
0.08%
Other
31.99%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
349
70.74M
49.14%
-18.33M
2025Q2
348
92.68M
75.53%
-5.84M
2025Q1
359
87.33M
71.43%
-8.58M
2024Q4
365
89.85M
74.79%
-8.38M
2024Q3
394
90.25M
75.21%
-25.05M
2024Q2
389
89.07M
76.08%
-29.09M
2024Q1
378
93.24M
79.93%
-23.55M
2023Q4
374
92.06M
79.14%
-28.03M
2023Q3
352
92.71M
80.23%
-26.22M
2023Q2
337
91.30M
79.07%
-24.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avista Capital Holdings, LP
15.82M
12.89%
--
--
Sep 30, 2024
Whitefort Capital Management, LP
10.24M
8.35%
+6.33M
+161.57%
Jun 30, 2025
Ash X LP
8.27M
6.74%
+2.86M
+52.77%
Aug 26, 2025
BlackRock Institutional Trust Company, N.A.
6.33M
5.16%
-122.32K
-1.89%
Jun 30, 2025
The Vanguard Group, Inc.
5.27M
4.29%
+89.01K
+1.72%
Jun 30, 2025
Foehr (Matthew W)
4.34M
3.53%
+540.54K
+14.24%
Aug 26, 2025
Higgins (John L)
2.85M
2.32%
+20.00K
+0.71%
Jun 17, 2025
Dimensional Fund Advisors, L.P.
2.91M
2.37%
-217.95K
-6.96%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
iShares Micro-Cap ETF
Proportion0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of OmniAb Inc?
The top five shareholders of OmniAb Inc are:
Avista Capital Holdings, LP holds 15.82M shares, accounting for 12.89% of the total shares.
Whitefort Capital Management, LP holds 10.24M shares, accounting for 8.35% of the total shares.
Ash X LP holds 8.27M shares, accounting for 6.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.33M shares, accounting for 5.16% of the total shares.
The Vanguard Group, Inc. holds 5.27M shares, accounting for 4.29% of the total shares.
Avista Capital Holdings, LP holds 15.82M shares, accounting for 12.89% of the total shares.
Whitefort Capital Management, LP holds 10.24M shares, accounting for 8.35% of the total shares.
Ash X LP holds 8.27M shares, accounting for 6.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.33M shares, accounting for 5.16% of the total shares.
The Vanguard Group, Inc. holds 5.27M shares, accounting for 4.29% of the total shares.
What are the top three shareholder types of OmniAb Inc?
The top three shareholder types of OmniAb Inc are:
Avista Capital Holdings, LP
Whitefort Capital Management, LP
Ash X LP
Avista Capital Holdings, LP
Whitefort Capital Management, LP
Ash X LP
How many institutions hold shares of OmniAb Inc (OABI)?
As of 2025Q3, 349 institutions hold shares of OmniAb Inc, with a combined market value of approximately 70.74M, accounting for 49.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -26.39%.
What is the biggest source of revenue for OmniAb Inc?
In FY2025Q2, the Service revenue business generated the highest revenue for OmniAb Inc, amounting to 1.94M and accounting for 49.68% of total revenue.
